semaglutide amino acid | GLP-1 receptor agonist | Type 2 diabetes Starting structure of semaglutide used

Across the full study period, NAION occurred in 45 semaglutide-treated patients compared with 29 patients receiving nonGLP-1 RA therapies, corresponding to absolute event rates of approximately 0.026% and 0.017%, respectively

But as with any medication, its important to understand the potential side effects before making a decision

If youre concerned, ask for a ferritin and thyroid check at your next blood test

(2024, April)

FDA-Approved Use of Ozempic Ozempic is FDA-approved as a glucagon-like peptide-1 (GLP-1) receptor agonist used: Alongside diet and exercise to improve blood sugar (glucose) levels in adults with type 2 diabetes To lower the risk of major cardiovascular events like heart attack, stroke, or death in adults with type 2 diabetes and known heart disease